Quviviq

Overview

daridorexant

orexin antagonist

• CYP3A4 substrate
• CYP3A4 inhibitor, weak
• P-gp inhibitor, weak
• CNS depression

Contraindicated

• cisapride
Quviviq (daridorexant)

+

cisapride

1 interaction

Contraindicated

daridorexant + cisapride

contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• colchicine
Quviviq (daridorexant)

+

colchicine

1 interaction

Contraindicated

daridorexant + colchicine

CV RISK REDUCTION: consider monitoring CK, myopathy s/sx; GOUT OR FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, use alternative or consider decr. colchicine dose during and x14 days after daridorexant use: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• eliglustat
Quviviq (daridorexant)

+

eliglustat

1 interaction

Contraindicated

daridorexant + eliglustat

CYP2D6 EM: contraindicated if Child-Pugh Class A and if also combined w/ moderate or strong CYP2D6 inhibitor; if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 IM: if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 PM: avoid combo: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• oxybate
Quviviq (daridorexant)

+

oxybate

1 interaction

Contraindicated

daridorexant + oxybate

contraindicated: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, syncope (additive effects)

Avoid/Use Alternative

• adagrasib
Quviviq (daridorexant)

+

adagrasib

1 interaction

Avoid/Use Alternative

daridorexant + adagrasib

avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• alprazolam
Quviviq (daridorexant)

+

alprazolam

1 interaction

Avoid/Use Alternative

daridorexant + alprazolam

use alternative or monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. levels of both drugs, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• apalutamide
Quviviq (daridorexant)

+

apalutamide

1 interaction

Avoid/Use Alternative

daridorexant + apalutamide

avoid combo: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• apixaban
Quviviq (daridorexant)

+

apixaban

1 interaction

Avoid/Use Alternative

daridorexant + apixaban

ADULT PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban 5mg bid or 10 mg bid dose by 50% or avoid combo if already on 2.5 mg bid; PEDS PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• atazanavir
Quviviq (daridorexant)

+

atazanavir

1 interaction

Avoid/Use Alternative

daridorexant + atazanavir

avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• bosentan
Quviviq (daridorexant)

+

bosentan

1 interaction

Avoid/Use Alternative

daridorexant + bosentan

avoid combo: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• butalbital
Quviviq (daridorexant)

+

butalbital

1 interaction

Avoid/Use Alternative

daridorexant + butalbital

avoid combo: combo may decr. daridorexant levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• carbamazepine
Quviviq (daridorexant)

+

carbamazepine

1 interaction

Avoid/Use Alternative

daridorexant + carbamazepine

avoid combo: combo may decr. daridorexant levels, efficacy; may incr. carbamazepine levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited, additive effects)

• cenobamate
Quviviq (daridorexant)

+

cenobamate

1 interaction

Avoid/Use Alternative

daridorexant + cenobamate

avoid combo: combo may decr. daridorexant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• ceritinib
Quviviq (daridorexant)

+

ceritinib

1 interaction

Avoid/Use Alternative

daridorexant + ceritinib

avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• chloramphenicol
Quviviq (daridorexant)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

daridorexant + chloramphenicol

avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• clarithromycin
Quviviq (daridorexant)

+

clarithromycin

1 interaction

Avoid/Use Alternative

daridorexant + clarithromycin

avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• clonidine
Quviviq (daridorexant)

+

clonidine

1 interaction

Avoid/Use Alternative

daridorexant + clonidine

if ADHD use, avoid combo; otherwise, consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cobicistat
Quviviq (daridorexant)

+

cobicistat

1 interaction

Avoid/Use Alternative

daridorexant + cobicistat

avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• codeine
Quviviq (daridorexant)

+

codeine

1 interaction

Avoid/Use Alternative

daridorexant + codeine

avoid combo if antitussive use; otherwise, use alternative or monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. codeine and active metabolite morphine levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, may incr. production of active metabolite morphine; additive effects)

• dabigatran
Quviviq (daridorexant)

+

dabigatran

1 interaction

Avoid/Use Alternative

daridorexant + dabigatran

ATRIAL FIBRILLATION: avoid combo if CrCl <30 mL/min; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; if dabigatran use for DVT/PE prophylaxis post-hip replacement and CrCl >50 mL/min, consider separating admin. at least 2h apart: combo may incr. dabigatran levels, risk of bleeding (including life-threatening), other adverse effects (P-gp-mediated transport inhibited)

• dabrafenib
Quviviq (daridorexant)

+

dabrafenib

1 interaction

Avoid/Use Alternative

daridorexant + dabrafenib

avoid combo: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• doxepin
Quviviq (daridorexant)

+

doxepin

1 interaction

Avoid/Use Alternative

daridorexant + doxepin

if doxepin insomnia use, avoid combo; otherwise, consider decr. dose of one of both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• doxylamine
Quviviq (daridorexant)

+

doxylamine

1 interaction

Avoid/Use Alternative

daridorexant + doxylamine

avoid combo if doxylamine use for pregnancy-related nausea/vomiting, otherwise consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• efavirenz
Quviviq (daridorexant)

+

efavirenz

1 interaction

Avoid/Use Alternative

daridorexant + efavirenz

avoid combo: combo may decr. daridorexant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• encorafenib
Quviviq (daridorexant)

+

encorafenib

1 interaction

Avoid/Use Alternative

daridorexant + encorafenib

avoid combo: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. daridorexant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• ensartinib
Quviviq (daridorexant)

+

ensartinib

1 interaction

Avoid/Use Alternative

daridorexant + ensartinib

avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (P-gp-mediated transport possibly inhibited)

• enzalutamide
Quviviq (daridorexant)

+

enzalutamide

1 interaction

Avoid/Use Alternative

daridorexant + enzalutamide

avoid combo: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• estazolam
Quviviq (daridorexant)

+

estazolam

1 interaction

Avoid/Use Alternative

daridorexant + estazolam

avoid combo: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• eszopiclone
Quviviq (daridorexant)

+

eszopiclone

1 interaction

Avoid/Use Alternative

daridorexant + eszopiclone

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ethanol
Quviviq (daridorexant)

+

ethanol

1 interaction

Avoid/Use Alternative

daridorexant + ethanol

ORAL ETHANOL: avoid combo; IV ETHANOL: use alternative or monitor respiratory rate; consider decreasing dose of one or both drugs: combo with oral ethanol or IV ethanol may increase risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• ethosuximide
Quviviq (daridorexant)

+

ethosuximide

1 interaction

Avoid/Use Alternative

daridorexant + ethosuximide

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• etravirine
Quviviq (daridorexant)

+

etravirine

1 interaction

Avoid/Use Alternative

daridorexant + etravirine

avoid combo: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• fexinidazole
Quviviq (daridorexant)

+

fexinidazole

1 interaction

Avoid/Use Alternative

daridorexant + fexinidazole

avoid combo: combo may decr. daridorexant levels, efficacy; may decr. fexinidazole active metabolite levels, efficacy (hepatic metabolism induced; hepatic metabolism inhibited, decr. conversion to active metabolites)

• flurazepam
Quviviq (daridorexant)

+

flurazepam

1 interaction

Avoid/Use Alternative

daridorexant + flurazepam

avoid combo: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• fosphenytoin
Quviviq (daridorexant)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

daridorexant + fosphenytoin

avoid combo: combo may decr. daridorexant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• haloperidol
Quviviq (daridorexant)

+

haloperidol

1 interaction

Avoid/Use Alternative

daridorexant + haloperidol

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• hydrocodone
Quviviq (daridorexant)

+

hydrocodone

1 interaction

Avoid/Use Alternative

daridorexant + hydrocodone

avoid combo if antitussive use; otherwise, use alternative or monitor respiratory rate, ECG; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. hydrocodone levels, risk of profound CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• idelalisib
Quviviq (daridorexant)

+

idelalisib

1 interaction

Avoid/Use Alternative

daridorexant + idelalisib

avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• isocarboxazid
Quviviq (daridorexant)

+

isocarboxazid

1 interaction

Avoid/Use Alternative

daridorexant + isocarboxazid

use alternative or consider decr. dose of one or both drugs during and x10 days after isocarboxazid use: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• itraconazole
Quviviq (daridorexant)

+

itraconazole

1 interaction

Avoid/Use Alternative

daridorexant + itraconazole

avoid combo during and x2wk after itraconazole tx: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• ivosidenib
Quviviq (daridorexant)

+

ivosidenib

1 interaction

Avoid/Use Alternative

daridorexant + ivosidenib

avoid combo: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. daridorexant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• kava
Quviviq (daridorexant)

+

kava

1 interaction

Avoid/Use Alternative

daridorexant + kava

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ketoconazole
Quviviq (daridorexant)

+

ketoconazole

1 interaction

Avoid/Use Alternative

daridorexant + ketoconazole

avoid combo during and up to 1wk after ketoconazole tx: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• kratom
Quviviq (daridorexant)

+

kratom

1 interaction

Avoid/Use Alternative

daridorexant + kratom

use alternative or monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. daridorexant levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• lemborexant
Quviviq (daridorexant)

+

lemborexant

1 interaction

Avoid/Use Alternative

daridorexant + lemborexant

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects, duplicate therapy)

• levoketoconazole
Quviviq (daridorexant)

+

levoketoconazole

1 interaction

Avoid/Use Alternative

daridorexant + levoketoconazole

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• lonafarnib
Quviviq (daridorexant)

+

lonafarnib

1 interaction

Avoid/Use Alternative

daridorexant + lonafarnib

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• lopinavir/ritonavir
Quviviq (daridorexant)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

daridorexant + lopinavir/ ritonavir

avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• lorazepam
Quviviq (daridorexant)

+

lorazepam

1 interaction

Avoid/Use Alternative

daridorexant + lorazepam

if lorazepam insomnia use, avoid combo; otherwise monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• lorlatinib
Quviviq (daridorexant)

+

lorlatinib

1 interaction

Avoid/Use Alternative

daridorexant + lorlatinib

avoid combo: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• lumacaftor/ivacaftor
Quviviq (daridorexant)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

daridorexant + lumacaftor/ ivacaftor

avoid combo: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• mavacamten
Quviviq (daridorexant)

+

mavacamten

1 interaction

Avoid/Use Alternative

daridorexant + mavacamten

avoid combo: combo may incr. mavacamten levels, risk of heart failure, other adverse effects; may decr. daridorexant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• meperidine
Quviviq (daridorexant)

+

meperidine

1 interaction

Avoid/Use Alternative

daridorexant + meperidine

use alternative or monitor respiratory rate, ECG; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. meperidine levels, risk of profound CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• metaxalone
Quviviq (daridorexant)

+

metaxalone

1 interaction

Avoid/Use Alternative

daridorexant + metaxalone

use alternative or monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• methadone
Quviviq (daridorexant)

+

methadone

1 interaction

Avoid/Use Alternative

daridorexant + methadone

use alternative or monitor respiratory rate, ECG; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. methadone levels, risk of profound CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• metoclopramide
Quviviq (daridorexant)

+

metoclopramide

1 interaction

Avoid/Use Alternative

daridorexant + metoclopramide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• midazolam
Quviviq (daridorexant)

+

midazolam

1 interaction

Avoid/Use Alternative

daridorexant + midazolam

use alternative or monitor respiratory rate; consider decr. dose of one or both drugs; use lowest effective doses and shortest duration of concomitant tx: combo may incr. midazolam and active metabolite levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• mifepristone
Quviviq (daridorexant)

+

mifepristone

1 interaction

Avoid/Use Alternative

daridorexant + mifepristone

avoid combo w/in 14 days of daily mifepristone use: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• mitapivat
Quviviq (daridorexant)

+

mitapivat

1 interaction

Avoid/Use Alternative

daridorexant + mitapivat

avoid combo: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• mitotane
Quviviq (daridorexant)

+

mitotane

1 interaction

Avoid/Use Alternative

daridorexant + mitotane

avoid combo: combo may decr. daridorexant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• modafinil
Quviviq (daridorexant)

+

modafinil

1 interaction

Avoid/Use Alternative

daridorexant + modafinil

avoid combo: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• nafcillin
Quviviq (daridorexant)

+

nafcillin

1 interaction

Avoid/Use Alternative

daridorexant + nafcillin

avoid combo: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• nefazodone
Quviviq (daridorexant)

+

nefazodone

1 interaction

Avoid/Use Alternative

daridorexant + nefazodone

avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• nelfinavir
Quviviq (daridorexant)

+

nelfinavir

1 interaction

Avoid/Use Alternative

daridorexant + nelfinavir

avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• neratinib
Quviviq (daridorexant)

+

neratinib

1 interaction

Avoid/Use Alternative

daridorexant + neratinib

avoid combo if also combined w/ mod-strong CYP3A4 inhibitor; otherwise, caution advised: combo may incr. neratinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• netupitant
Quviviq (daridorexant)

+

netupitant

1 interaction

Avoid/Use Alternative

daridorexant + netupitant

use alternative or adjust max daridorexant dose to 25 mg/day dose during and x1wk after (fos)netupitant tx: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• oxycodone
Quviviq (daridorexant)

+

oxycodone

1 interaction

Avoid/Use Alternative

daridorexant + oxycodone

use alternative or monitor respiratory rate; decr. oxycodone start dose by at least 50%, consider decr. daridorexant dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. oxycodone levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• pacritinib
Quviviq (daridorexant)

+

pacritinib

1 interaction

Avoid/Use Alternative

daridorexant + pacritinib

avoid combo: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (including life-threatening), other adverse effects; may decr. daridorexant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• pentobarbital
Quviviq (daridorexant)

+

pentobarbital

1 interaction

Avoid/Use Alternative

daridorexant + pentobarbital

avoid combo: combo may decr. daridorexant levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• pexidartinib
Quviviq (daridorexant)

+

pexidartinib

1 interaction

Avoid/Use Alternative

daridorexant + pexidartinib

avoid combo: combo may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects; may decr. daridorexant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• phenelzine
Quviviq (daridorexant)

+

phenelzine

1 interaction

Avoid/Use Alternative

daridorexant + phenelzine

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• phenobarbital
Quviviq (daridorexant)

+

phenobarbital

1 interaction

Avoid/Use Alternative

daridorexant + phenobarbital

avoid combo: combo may decr. daridorexant levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• phenytoin
Quviviq (daridorexant)

+

phenytoin

1 interaction

Avoid/Use Alternative

daridorexant + phenytoin

avoid combo: combo may decr. daridorexant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• pimozide
Quviviq (daridorexant)

+

pimozide

1 interaction

Avoid/Use Alternative

daridorexant + pimozide

use alternative or monitor ECG; consider decr. dose of one or both drugs: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• posaconazole
Quviviq (daridorexant)

+

posaconazole

1 interaction

Avoid/Use Alternative

daridorexant + posaconazole

avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• pralsetinib
Quviviq (daridorexant)

+

pralsetinib

1 interaction

Avoid/Use Alternative

daridorexant + pralsetinib

use alternative or consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• primidone
Quviviq (daridorexant)

+

primidone

1 interaction

Avoid/Use Alternative

daridorexant + primidone

avoid combo: combo may decr. daridorexant levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• promethazine
Quviviq (daridorexant)

+

promethazine

1 interaction

Avoid/Use Alternative

daridorexant + promethazine

use alternative or monitor respiratory rate; decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• propafenone
Quviviq (daridorexant)

+

propafenone

1 interaction

Avoid/Use Alternative

daridorexant + propafenone

if CYP2D6 poor metabolizer or if also combined w/ CYP2D6 inhibitor, avoid combo; otherwise, monitor ECG, BP: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metabolism inhibited)

• quazepam
Quviviq (daridorexant)

+

quazepam

1 interaction

Avoid/Use Alternative

daridorexant + quazepam

avoid combo: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• ramelteon
Quviviq (daridorexant)

+

ramelteon

1 interaction

Avoid/Use Alternative

daridorexant + ramelteon

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• relugolix
Quviviq (daridorexant)

+

relugolix

1 interaction

Avoid/Use Alternative

daridorexant + relugolix

PROSTATE CANCER: may hold relugolix if daridorexant tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before daridorexant; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before daridorexant: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• repotrectinib
Quviviq (daridorexant)

+

repotrectinib

1 interaction

Avoid/Use Alternative

daridorexant + repotrectinib

avoid combo: combo may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, other adverse effects; may decr. daridorexant levels, efficacy (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects; hepatic metabolism induced)

• ribociclib
Quviviq (daridorexant)

+

ribociclib

1 interaction

Avoid/Use Alternative

daridorexant + ribociclib

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• rifabutin
Quviviq (daridorexant)

+

rifabutin

1 interaction

Avoid/Use Alternative

daridorexant + rifabutin

avoid combo: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• rifampin
Quviviq (daridorexant)

+

rifampin

1 interaction

Avoid/Use Alternative

daridorexant + rifampin

avoid combo: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• rifapentine
Quviviq (daridorexant)

+

rifapentine

1 interaction

Avoid/Use Alternative

daridorexant + rifapentine

avoid combo: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• ritonavir
Quviviq (daridorexant)

+

ritonavir

1 interaction

Avoid/Use Alternative

daridorexant + ritonavir

avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• rivaroxaban
Quviviq (daridorexant)

+

rivaroxaban

1 interaction

Avoid/Use Alternative

daridorexant + rivaroxaban

avoid combo if also combined w/ strong CYP3A4 inhibitor; use alternative if CrCl <80 and combined w/ moderate CYP3A4 inhibitor; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• ropeginterferon alfa-2b
Quviviq (daridorexant)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

daridorexant + ropeginterferon alfa-2b

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• scopolamine
Quviviq (daridorexant)

+

scopolamine

1 interaction

Avoid/Use Alternative

daridorexant + scopolamine

use alternative or consider decreasing dose of one or both drugs: combo may increase risk of CNS depression, psychomotor impairment (additive effects)

• simvastatin
Quviviq (daridorexant)

+

simvastatin

1 interaction

Avoid/Use Alternative

daridorexant + simvastatin

use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 20 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

• sirolimus albumin-bound
Quviviq (daridorexant)

+

sirolimus albumin-bound

1 interaction

Avoid/Use Alternative

daridorexant + sirolimus albumin-bound

avoid combo: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• sotorasib
Quviviq (daridorexant)

+

sotorasib

1 interaction

Avoid/Use Alternative

daridorexant + sotorasib

avoid combo: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• St. John's wort
Quviviq (daridorexant)

+

St. John's wort

1 interaction

Avoid/Use Alternative

daridorexant + St. John's wort

avoid combo: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• suvorexant
Quviviq (daridorexant)

+

suvorexant

1 interaction

Avoid/Use Alternative

daridorexant + suvorexant

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects, duplicate therapy)

• tasimelteon
Quviviq (daridorexant)

+

tasimelteon

1 interaction

Avoid/Use Alternative

daridorexant + tasimelteon

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• temazepam
Quviviq (daridorexant)

+

temazepam

1 interaction

Avoid/Use Alternative

daridorexant + temazepam

avoid combo: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• thalidomide
Quviviq (daridorexant)

+

thalidomide

1 interaction

Avoid/Use Alternative

daridorexant + thalidomide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tipranavir
Quviviq (daridorexant)

+

tipranavir

1 interaction

Avoid/Use Alternative

daridorexant + tipranavir

avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• topotecan
Quviviq (daridorexant)

+

topotecan

1 interaction

Avoid/Use Alternative

daridorexant + topotecan

avoid combo w/ oral topotecan: combo may incr. topotecan levels, risk of serious infection, myelosuppression, other adverse effects (gut P-gp-mediated transport inhibited)

• tradipitant
Quviviq (daridorexant)

+

tradipitant

1 interaction

Avoid/Use Alternative

daridorexant + tradipitant

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tranylcypromine
Quviviq (daridorexant)

+

tranylcypromine

1 interaction

Avoid/Use Alternative

daridorexant + tranylcypromine

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• triazolam
Quviviq (daridorexant)

+

triazolam

1 interaction

Avoid/Use Alternative

daridorexant + triazolam

avoid combo: combo may incr. triazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• trimethobenzamide
Quviviq (daridorexant)

+

trimethobenzamide

1 interaction

Avoid/Use Alternative

daridorexant + trimethobenzamide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tucatinib
Quviviq (daridorexant)

+

tucatinib

1 interaction

Avoid/Use Alternative

daridorexant + tucatinib

avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• venetoclax
Quviviq (daridorexant)

+

venetoclax

1 interaction

Avoid/Use Alternative

daridorexant + venetoclax

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• voriconazole
Quviviq (daridorexant)

+

voriconazole

1 interaction

Avoid/Use Alternative

daridorexant + voriconazole

avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• zaleplon
Quviviq (daridorexant)

+

zaleplon

1 interaction

Avoid/Use Alternative

daridorexant + zaleplon

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zolpidem
Quviviq (daridorexant)

+

zolpidem

1 interaction

Avoid/Use Alternative

daridorexant + zolpidem

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zuranolone
Quviviq (daridorexant)

+

zuranolone

1 interaction

Avoid/Use Alternative

daridorexant + zuranolone

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Monitor/Modify Tx

• 5-HTP
Quviviq (daridorexant)

+

5-HTP

1 interaction

Monitor/Modify Tx

daridorexant + 5-HTP

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• abemaciclib
Quviviq (daridorexant)

+

abemaciclib

1 interaction

Monitor/Modify Tx

daridorexant + abemaciclib

monitor CBC: combo may incr. abemaciclib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• acalabrutinib
Quviviq (daridorexant)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

daridorexant + acalabrutinib

monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• afatinib
Quviviq (daridorexant)

+

afatinib

1 interaction

Monitor/Modify Tx

daridorexant + afatinib

decr. afatinib dose by 10 mg/day if not tolerated: combo may incr. afatinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• aldesleukin
Quviviq (daridorexant)

+

aldesleukin

1 interaction

Monitor/Modify Tx

daridorexant + aldesleukin

consider decr. dose of one or both drugs; withhold aldesleukin if mod-severe somnolence occurs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• alfentanil
Quviviq (daridorexant)

+

alfentanil

1 interaction

Monitor/Modify Tx

daridorexant + alfentanil

monitor BP, respiratory rate; decr. dose of one or both drugs: combo may incr. alfentanil levels, risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, delayed recovery from anesthesia, other adverse effects (hepatic metabolism inhibited, additive effects)

• allopurinol
Quviviq (daridorexant)

+

allopurinol

1 interaction

Monitor/Modify Tx

daridorexant + allopurinol

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• almotriptan
Quviviq (daridorexant)

+

almotriptan

1 interaction

Monitor/Modify Tx

daridorexant + almotriptan

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• amantadine
Quviviq (daridorexant)

+

amantadine

1 interaction

Monitor/Modify Tx

daridorexant + amantadine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• amiodarone
Quviviq (daridorexant)

+

amiodarone

1 interaction

Monitor/Modify Tx

daridorexant + amiodarone

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• amitriptyline
Quviviq (daridorexant)

+

amitriptyline

1 interaction

Monitor/Modify Tx

daridorexant + amitriptyline

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• amoxapine
Quviviq (daridorexant)

+

amoxapine

1 interaction

Monitor/Modify Tx

daridorexant + amoxapine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• apomorphine
Quviviq (daridorexant)

+

apomorphine

1 interaction

Monitor/Modify Tx

daridorexant + apomorphine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• apraclonidine ophthalmic
Quviviq (daridorexant)

+

apraclonidine ophthalmic

1 interaction

Monitor/Modify Tx

daridorexant + apraclonidine ophthalmic

consider decr. dose of one or both drugs if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aprepitant
Quviviq (daridorexant)

+

aprepitant

1 interaction

Monitor/Modify Tx

daridorexant + aprepitant

if aprepitant 3-day regimen, adjust max daridorexant dose to 25 mg/day; aprepitant single dose-regimen OK: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• aripiprazole bimonthly injection
Quviviq (daridorexant)

+

aripiprazole bimonthly injection

1 interaction

Monitor/Modify Tx

daridorexant + aripiprazole bimonthly injection

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aripiprazole lauroxil
Quviviq (daridorexant)

+

aripiprazole lauroxil

1 interaction

Monitor/Modify Tx

daridorexant + aripiprazole lauroxil

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aripiprazole monthly injection
Quviviq (daridorexant)

+

aripiprazole monthly injection

1 interaction

Monitor/Modify Tx

daridorexant + aripiprazole monthly injection

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aripiprazole oral
Quviviq (daridorexant)

+

aripiprazole oral

1 interaction

Monitor/Modify Tx

daridorexant + aripiprazole oral

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• asenapine
Quviviq (daridorexant)

+

asenapine

1 interaction

Monitor/Modify Tx

daridorexant + asenapine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• atorvastatin
Quviviq (daridorexant)

+

atorvastatin

1 interaction

Monitor/Modify Tx

daridorexant + atorvastatin

monitor CK, myopathy sx: combo may incr. levels of both drugs, risk of myopathy, rhabdomyolysis, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• avacopan
Quviviq (daridorexant)

+

avacopan

1 interaction

Monitor/Modify Tx

daridorexant + avacopan

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• avanafil
Quviviq (daridorexant)

+

avanafil

1 interaction

Monitor/Modify Tx

daridorexant + avanafil

monitor BP; consider decr. avanafil dose: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

• avapritinib
Quviviq (daridorexant)

+

avapritinib

1 interaction

Monitor/Modify Tx

daridorexant + avapritinib

monitor bleeding s/sx: combo may incr. avapritinib levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

• baclofen
Quviviq (daridorexant)

+

baclofen

1 interaction

Monitor/Modify Tx

daridorexant + baclofen

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• baclofen intrathecal
Quviviq (daridorexant)

+

baclofen intrathecal

1 interaction

Monitor/Modify Tx

daridorexant + baclofen intrathecal

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• berotralstat
Quviviq (daridorexant)

+

berotralstat

1 interaction

Monitor/Modify Tx

daridorexant + berotralstat

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• brexpiprazole
Quviviq (daridorexant)

+

brexpiprazole

1 interaction

Monitor/Modify Tx

daridorexant + brexpiprazole

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brigatinib
Quviviq (daridorexant)

+

brigatinib

1 interaction

Monitor/Modify Tx

daridorexant + brigatinib

monitor BP, HR: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects; may decr. daridorexant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• brimonidine topical
Quviviq (daridorexant)

+

brimonidine topical

1 interaction

Monitor/Modify Tx

daridorexant + brimonidine topical

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brivaracetam
Quviviq (daridorexant)

+

brivaracetam

1 interaction

Monitor/Modify Tx

daridorexant + brivaracetam

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• bromocriptine
Quviviq (daridorexant)

+

bromocriptine

1 interaction

Monitor/Modify Tx

daridorexant + bromocriptine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brompheniramine
Quviviq (daridorexant)

+

brompheniramine

1 interaction

Monitor/Modify Tx

daridorexant + brompheniramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• buprenorphine
Quviviq (daridorexant)

+

buprenorphine

1 interaction

Monitor/Modify Tx

daridorexant + buprenorphine

monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• buspirone
Quviviq (daridorexant)

+

buspirone

1 interaction

Monitor/Modify Tx

daridorexant + buspirone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• butorphanol
Quviviq (daridorexant)

+

butorphanol

1 interaction

Monitor/Modify Tx

daridorexant + butorphanol

monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• cannabidiol
Quviviq (daridorexant)

+

cannabidiol

1 interaction

Monitor/Modify Tx

daridorexant + cannabidiol

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cannabis
Quviviq (daridorexant)

+

cannabis

1 interaction

Monitor/Modify Tx

daridorexant + cannabis

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• capivasertib
Quviviq (daridorexant)

+

capivasertib

1 interaction

Monitor/Modify Tx

daridorexant + capivasertib

monitor glucose: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• carbinoxamine
Quviviq (daridorexant)

+

carbinoxamine

1 interaction

Monitor/Modify Tx

daridorexant + carbinoxamine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cariprazine
Quviviq (daridorexant)

+

cariprazine

1 interaction

Monitor/Modify Tx

daridorexant + cariprazine

consider decr. dose of one or both drugs: combo may incr. cariprazine and active metabolite levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• carisoprodol
Quviviq (daridorexant)

+

carisoprodol

1 interaction

Monitor/Modify Tx

daridorexant + carisoprodol

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cetirizine
Quviviq (daridorexant)

+

cetirizine

1 interaction

Monitor/Modify Tx

daridorexant + cetirizine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chamomile, German
Quviviq (daridorexant)

+

chamomile, German

1 interaction

Monitor/Modify Tx

daridorexant + chamomile, German

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlophedianol
Quviviq (daridorexant)

+

chlophedianol

1 interaction

Monitor/Modify Tx

daridorexant + chlophedianol

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlorcyclizine
Quviviq (daridorexant)

+

chlorcyclizine

1 interaction

Monitor/Modify Tx

daridorexant + chlorcyclizine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlordiazepoxide
Quviviq (daridorexant)

+

chlordiazepoxide

1 interaction

Monitor/Modify Tx

daridorexant + chlordiazepoxide

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• chlorpheniramine
Quviviq (daridorexant)

+

chlorpheniramine

1 interaction

Monitor/Modify Tx

daridorexant + chlorpheniramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlorpromazine
Quviviq (daridorexant)

+

chlorpromazine

1 interaction

Monitor/Modify Tx

daridorexant + chlorpromazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlorzoxazone
Quviviq (daridorexant)

+

chlorzoxazone

1 interaction

Monitor/Modify Tx

daridorexant + chlorzoxazone

consider decr. dose of one or both drugs: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• ciprofloxacin
Quviviq (daridorexant)

+

ciprofloxacin

1 interaction

Monitor/Modify Tx

daridorexant + ciprofloxacin

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• citalopram
Quviviq (daridorexant)

+

citalopram

1 interaction

Monitor/Modify Tx

daridorexant + citalopram

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• clemastine
Quviviq (daridorexant)

+

clemastine

1 interaction

Monitor/Modify Tx

daridorexant + clemastine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• clobazam
Quviviq (daridorexant)

+

clobazam

1 interaction

Monitor/Modify Tx

daridorexant + clobazam

monitor respiratory rate; consider dose adjustment of one or both drugs: combo may decr. daridorexant levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• clofazimine
Quviviq (daridorexant)

+

clofazimine

1 interaction

Monitor/Modify Tx

daridorexant + clofazimine

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• clomipramine
Quviviq (daridorexant)

+

clomipramine

1 interaction

Monitor/Modify Tx

daridorexant + clomipramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• clonazepam
Quviviq (daridorexant)

+

clonazepam

1 interaction

Monitor/Modify Tx

daridorexant + clonazepam

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• clorazepate
Quviviq (daridorexant)

+

clorazepate

1 interaction

Monitor/Modify Tx

daridorexant + clorazepate

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• clozapine
Quviviq (daridorexant)

+

clozapine

1 interaction

Monitor/Modify Tx

daridorexant + clozapine

monitor ECG, BP, HR; consider decr. dose of one or both drugs: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• conivaptan
Quviviq (daridorexant)

+

conivaptan

1 interaction

Monitor/Modify Tx

daridorexant + conivaptan

adjust max daridorexant dose to 25 mg/day during and x7 days after conivaptan tx: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, overly rapid serum sodium correction, neurologic sequelae, other adverse effects (hepatic metabolism inhibited)

• crizotinib
Quviviq (daridorexant)

+

crizotinib

1 interaction

Monitor/Modify Tx

daridorexant + crizotinib

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• cyclobenzaprine
Quviviq (daridorexant)

+

cyclobenzaprine

1 interaction

Monitor/Modify Tx

daridorexant + cyclobenzaprine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cyclosporine
Quviviq (daridorexant)

+

cyclosporine

1 interaction

Monitor/Modify Tx

daridorexant + cyclosporine

monitor cyclosporine levels, renal fxn; adjust max daridorexant dose to 25 mg/day: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, serious infection, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• cyproheptadine
Quviviq (daridorexant)

+

cyproheptadine

1 interaction

Monitor/Modify Tx

daridorexant + cyproheptadine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• danazol
Quviviq (daridorexant)

+

danazol

1 interaction

Monitor/Modify Tx

daridorexant + danazol

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• dantrolene
Quviviq (daridorexant)

+

dantrolene

1 interaction

Monitor/Modify Tx

daridorexant + dantrolene

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• darifenacin
Quviviq (daridorexant)

+

darifenacin

1 interaction

Monitor/Modify Tx

daridorexant + darifenacin

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• darunavir
Quviviq (daridorexant)

+

darunavir

1 interaction

Monitor/Modify Tx

daridorexant + darunavir

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• desflurane
Quviviq (daridorexant)

+

desflurane

1 interaction

Monitor/Modify Tx

daridorexant + desflurane

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• desipramine
Quviviq (daridorexant)

+

desipramine

1 interaction

Monitor/Modify Tx

daridorexant + desipramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• desvenlafaxine
Quviviq (daridorexant)

+

desvenlafaxine

1 interaction

Monitor/Modify Tx

daridorexant + desvenlafaxine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• deutetrabenazine
Quviviq (daridorexant)

+

deutetrabenazine

1 interaction

Monitor/Modify Tx

daridorexant + deutetrabenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexbrompheniramine
Quviviq (daridorexant)

+

dexbrompheniramine

1 interaction

Monitor/Modify Tx

daridorexant + dexbrompheniramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexchlorpheniramine
Quviviq (daridorexant)

+

dexchlorpheniramine

1 interaction

Monitor/Modify Tx

daridorexant + dexchlorpheniramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexmedetomidine
Quviviq (daridorexant)

+

dexmedetomidine

1 interaction

Monitor/Modify Tx

daridorexant + dexmedetomidine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexmedetomidine injection
Quviviq (daridorexant)

+

dexmedetomidine injection

1 interaction

Monitor/Modify Tx

daridorexant + dexmedetomidine injection

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• diazepam
Quviviq (daridorexant)

+

diazepam

1 interaction

Monitor/Modify Tx

daridorexant + diazepam

monitor respiratory rate; consider decr. dose of one or both drugs; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• dichlorphenamide
Quviviq (daridorexant)

+

dichlorphenamide

1 interaction

Monitor/Modify Tx

daridorexant + dichlorphenamide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• difelikefalin
Quviviq (daridorexant)

+

difelikefalin

1 interaction

Monitor/Modify Tx

daridorexant + difelikefalin

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• difenoxin
Quviviq (daridorexant)

+

difenoxin

1 interaction

Monitor/Modify Tx

daridorexant + difenoxin

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• digoxin
Quviviq (daridorexant)

+

digoxin

1 interaction

Monitor/Modify Tx

daridorexant + digoxin

monitor digoxin levels, HR; decr. digoxin frequency or dose by 15-30%: combo may incr. digoxin levels, risk of bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited)

• dihydrocodeine
Quviviq (daridorexant)

+

dihydrocodeine

1 interaction

Monitor/Modify Tx

daridorexant + dihydrocodeine

monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• diltiazem
Quviviq (daridorexant)

+

diltiazem

1 interaction

Monitor/Modify Tx

daridorexant + diltiazem

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• dimenhydrinate
Quviviq (daridorexant)

+

dimenhydrinate

1 interaction

Monitor/Modify Tx

daridorexant + dimenhydrinate

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• diphenhydramine
Quviviq (daridorexant)

+

diphenhydramine

1 interaction

Monitor/Modify Tx

daridorexant + diphenhydramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• diphenoxylate
Quviviq (daridorexant)

+

diphenoxylate

1 interaction

Monitor/Modify Tx

daridorexant + diphenoxylate

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• disopyramide
Quviviq (daridorexant)

+

disopyramide

1 interaction

Monitor/Modify Tx

daridorexant + disopyramide

monitor disopyramide levels, ECG: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• docetaxel
Quviviq (daridorexant)

+

docetaxel

1 interaction

Monitor/Modify Tx

daridorexant + docetaxel

monitor CBC: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• dofetilide
Quviviq (daridorexant)

+

dofetilide

1 interaction

Monitor/Modify Tx

daridorexant + dofetilide

monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• domperidone
Quviviq (daridorexant)

+

domperidone

1 interaction

Monitor/Modify Tx

daridorexant + domperidone

monitor ECG, HR, electrolytes: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• doxepin topical
Quviviq (daridorexant)

+

doxepin topical

1 interaction

Monitor/Modify Tx

daridorexant + doxepin topical

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dronabinol
Quviviq (daridorexant)

+

dronabinol

1 interaction

Monitor/Modify Tx

daridorexant + dronabinol

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dronedarone
Quviviq (daridorexant)

+

dronedarone

1 interaction

Monitor/Modify Tx

daridorexant + dronedarone

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• droperidol
Quviviq (daridorexant)

+

droperidol

1 interaction

Monitor/Modify Tx

daridorexant + droperidol

decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• duloxetine
Quviviq (daridorexant)

+

duloxetine

1 interaction

Monitor/Modify Tx

daridorexant + duloxetine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• duvelisib
Quviviq (daridorexant)

+

duvelisib

1 interaction

Monitor/Modify Tx

daridorexant + duvelisib

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• edoxaban
Quviviq (daridorexant)

+

edoxaban

1 interaction

Monitor/Modify Tx

daridorexant + edoxaban

monitor bleeding s/sx: combo may incr. edoxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• eletriptan
Quviviq (daridorexant)

+

eletriptan

1 interaction

Monitor/Modify Tx

daridorexant + eletriptan

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• elinzanetant
Quviviq (daridorexant)

+

elinzanetant

1 interaction

Monitor/Modify Tx

daridorexant + elinzanetant

consider decr. dose of one or both drugs: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• enfortumab vedotin
Quviviq (daridorexant)

+

enfortumab vedotin

1 interaction

Monitor/Modify Tx

daridorexant + enfortumab vedotin

if also combined w/ strong CYP3A4 inhibitor, monitor CBC, glucose: combo may incr. enfortumab vedotin levels, risk of myelosuppression, neuropathy, hyperglycemia, other adverse effects (P-gp-mediated transport inhibited)

• entacapone
Quviviq (daridorexant)

+

entacapone

1 interaction

Monitor/Modify Tx

daridorexant + entacapone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• entrectinib
Quviviq (daridorexant)

+

entrectinib

1 interaction

Monitor/Modify Tx

daridorexant + entrectinib

monitor CBC, ECG; consider decr. dose of one or both drugs: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• eplerenone
Quviviq (daridorexant)

+

eplerenone

1 interaction

Monitor/Modify Tx

daridorexant + eplerenone

monitor potassium: combo may incr. eplerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

• erythromycin
Quviviq (daridorexant)

+

erythromycin

1 interaction

Monitor/Modify Tx

daridorexant + erythromycin

monitor ECG; adjust max daridorexant dose to 25 mg/day: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• escitalopram
Quviviq (daridorexant)

+

escitalopram

1 interaction

Monitor/Modify Tx

daridorexant + escitalopram

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• esketamine
Quviviq (daridorexant)

+

esketamine

1 interaction

Monitor/Modify Tx

daridorexant + esketamine

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• eslicarbazepine acetate
Quviviq (daridorexant)

+

eslicarbazepine acetate

1 interaction

Monitor/Modify Tx

daridorexant + eslicarbazepine acetate

consider dose adjustment of one or both drugs: combo may decr. daridorexant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• ethanol (in some formulations)
Quviviq (daridorexant)

+

ethanol (in some formulations)

1 interaction

Monitor/Modify Tx

daridorexant + ethanol (in some formulations)

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• etomidate
Quviviq (daridorexant)

+

etomidate

1 interaction

Monitor/Modify Tx

daridorexant + etomidate

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• everolimus
Quviviq (daridorexant)

+

everolimus

1 interaction

Monitor/Modify Tx

daridorexant + everolimus

TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC; OTHER INDICATIONS: monitor CBC: combo may incr. levels of both drugs, risk of myelosuppression, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• fedratinib
Quviviq (daridorexant)

+

fedratinib

1 interaction

Monitor/Modify Tx

daridorexant + fedratinib

adjust max daridorexant dose to 25 mg/day; if fedratinib also combined w/ CYP2C19 inhibitor, monitor CBC, LFTs: combo may incr. levels of both drugs, risk of myelosuppression, hepatotoxicity, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• felbamate
Quviviq (daridorexant)

+

felbamate

1 interaction

Monitor/Modify Tx

daridorexant + felbamate

consider dose adjustment of one or both drugs: combo may decr. daridorexant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• felodipine
Quviviq (daridorexant)

+

felodipine

1 interaction

Monitor/Modify Tx

daridorexant + felodipine

monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects (hepatic metabolism inhibited)

• fenfluramine
Quviviq (daridorexant)

+

fenfluramine

1 interaction

Monitor/Modify Tx

daridorexant + fenfluramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fentanyl
Quviviq (daridorexant)

+

fentanyl

1 interaction

Monitor/Modify Tx

daridorexant + fentanyl

monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. fentanyl levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• fesoterodine
Quviviq (daridorexant)

+

fesoterodine

1 interaction

Monitor/Modify Tx

daridorexant + fesoterodine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• finerenone
Quviviq (daridorexant)

+

finerenone

1 interaction

Monitor/Modify Tx

daridorexant + finerenone

monitor potassium: combo may incr. levels of both drugs, risk of hyperkalemia, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• flibanserin
Quviviq (daridorexant)

+

flibanserin

1 interaction

Monitor/Modify Tx

daridorexant + flibanserin

monitor BP, especially if flibanserin also combined w/ other weak CYP3A4 inhibitors; consider decr. dose of one or both drugs: combo may incr. levels of both drugs, risk of risk of CNS depression, psychomotor impairment, severe hypotension (including syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• fluconazole
Quviviq (daridorexant)

+

fluconazole

1 interaction

Monitor/Modify Tx

daridorexant + fluconazole

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• fluoxetine
Quviviq (daridorexant)

+

fluoxetine

1 interaction

Monitor/Modify Tx

daridorexant + fluoxetine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fluphenazine
Quviviq (daridorexant)

+

fluphenazine

1 interaction

Monitor/Modify Tx

daridorexant + fluphenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fluvoxamine
Quviviq (daridorexant)

+

fluvoxamine

1 interaction

Monitor/Modify Tx

daridorexant + fluvoxamine

consider decr. dose of one or both drugs: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• fosamprenavir
Quviviq (daridorexant)

+

fosamprenavir

1 interaction

Monitor/Modify Tx

daridorexant + fosamprenavir

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• foslevodopa
Quviviq (daridorexant)

+

foslevodopa

1 interaction

Monitor/Modify Tx

daridorexant + foslevodopa

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• frovatriptan
Quviviq (daridorexant)

+

frovatriptan

1 interaction

Monitor/Modify Tx

daridorexant + frovatriptan

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• gabapentin
Quviviq (daridorexant)

+

gabapentin

1 interaction

Monitor/Modify Tx

daridorexant + gabapentin

monitor respiratory rate; consider decreasing dose of one or both drugs: combo may increase risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• gabapentin enacarbil
Quviviq (daridorexant)

+

gabapentin enacarbil

1 interaction

Monitor/Modify Tx

daridorexant + gabapentin enacarbil

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• ganaxolone
Quviviq (daridorexant)

+

ganaxolone

1 interaction

Monitor/Modify Tx

daridorexant + ganaxolone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• gepirone
Quviviq (daridorexant)

+

gepirone

1 interaction

Monitor/Modify Tx

daridorexant + gepirone

monitor ECG, electrolytes: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• glofitamab
Quviviq (daridorexant)

+

glofitamab

1 interaction

Monitor/Modify Tx

daridorexant + glofitamab

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• glycopyrrolate
Quviviq (daridorexant)

+

glycopyrrolate

1 interaction

Monitor/Modify Tx

daridorexant + glycopyrrolate

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• grapefruit
Quviviq (daridorexant)

+

grapefruit

1 interaction

Monitor/Modify Tx

daridorexant + grapefruit

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (GI metabolism inhibited)

• guanfacine
Quviviq (daridorexant)

+

guanfacine

1 interaction

Monitor/Modify Tx

daridorexant + guanfacine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• hydromorphone
Quviviq (daridorexant)

+

hydromorphone

1 interaction

Monitor/Modify Tx

daridorexant + hydromorphone

monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• hydroxyzine
Quviviq (daridorexant)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

daridorexant + hydroxyzine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• hyoscyamine
Quviviq (daridorexant)

+

hyoscyamine

1 interaction

Monitor/Modify Tx

daridorexant + hyoscyamine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ibrutinib
Quviviq (daridorexant)

+

ibrutinib

1 interaction

Monitor/Modify Tx

daridorexant + ibrutinib

consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• ifosfamide
Quviviq (daridorexant)

+

ifosfamide

1 interaction

Monitor/Modify Tx

daridorexant + ifosfamide

consider decr. daridorexant dose; D/C one or both drugs if encephalopathy occurs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• iloperidone
Quviviq (daridorexant)

+

iloperidone

1 interaction

Monitor/Modify Tx

daridorexant + iloperidone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• imatinib
Quviviq (daridorexant)

+

imatinib

1 interaction

Monitor/Modify Tx

daridorexant + imatinib

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• imipramine
Quviviq (daridorexant)

+

imipramine

1 interaction

Monitor/Modify Tx

daridorexant + imipramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• isavuconazonium
Quviviq (daridorexant)

+

isavuconazonium

1 interaction

Monitor/Modify Tx

daridorexant + isavuconazonium

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• isoflurane
Quviviq (daridorexant)

+

isoflurane

1 interaction

Monitor/Modify Tx

daridorexant + isoflurane

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• ivabradine
Quviviq (daridorexant)

+

ivabradine

1 interaction

Monitor/Modify Tx

daridorexant + ivabradine

monitor HR, ECG: combo may incr. ivabradine levels, risk of bradycardia, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ixabepilone
Quviviq (daridorexant)

+

ixabepilone

1 interaction

Monitor/Modify Tx

daridorexant + ixabepilone

monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metabolism inhibited)

• ketamine
Quviviq (daridorexant)

+

ketamine

1 interaction

Monitor/Modify Tx

daridorexant + ketamine

monitor respiratory rate; consider decr. dose of one or both drugs; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression (including life-threatening), psychomotor impairment (additive effects)

• lacosamide
Quviviq (daridorexant)

+

lacosamide

1 interaction

Monitor/Modify Tx

daridorexant + lacosamide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lamotrigine
Quviviq (daridorexant)

+

lamotrigine

1 interaction

Monitor/Modify Tx

daridorexant + lamotrigine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lefamulin
Quviviq (daridorexant)

+

lefamulin

1 interaction

Monitor/Modify Tx

daridorexant + lefamulin

ORAL LEFAMULIN: adjust max daridorexant dose to 25 mg/day; IV lefamulin use OK: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• lenacapavir
Quviviq (daridorexant)

+

lenacapavir

1 interaction

Monitor/Modify Tx

daridorexant + lenacapavir

adjust max daridorexant dose to 25 mg/day during and x9mo after lenacapavir tx: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• letermovir
Quviviq (daridorexant)

+

letermovir

1 interaction

Monitor/Modify Tx

daridorexant + letermovir

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• levetiracetam
Quviviq (daridorexant)

+

levetiracetam

1 interaction

Monitor/Modify Tx

daridorexant + levetiracetam

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levocetirizine
Quviviq (daridorexant)

+

levocetirizine

1 interaction

Monitor/Modify Tx

daridorexant + levocetirizine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levodopa
Quviviq (daridorexant)

+

levodopa

1 interaction

Monitor/Modify Tx

daridorexant + levodopa

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levomilnacipran
Quviviq (daridorexant)

+

levomilnacipran

1 interaction

Monitor/Modify Tx

daridorexant + levomilnacipran

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levorphanol
Quviviq (daridorexant)

+

levorphanol

1 interaction

Monitor/Modify Tx

daridorexant + levorphanol

monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• linvoseltamab
Quviviq (daridorexant)

+

linvoseltamab

1 interaction

Monitor/Modify Tx

daridorexant + linvoseltamab

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lofexidine
Quviviq (daridorexant)

+

lofexidine

1 interaction

Monitor/Modify Tx

daridorexant + lofexidine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lomitapide
Quviviq (daridorexant)

+

lomitapide

1 interaction

Monitor/Modify Tx

daridorexant + lomitapide

max lomitapide dose 30 mg/day: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

• lovastatin
Quviviq (daridorexant)

+

lovastatin

1 interaction

Monitor/Modify Tx

daridorexant + lovastatin

monitor CK, myopathy sx: combo may incr. levels of both drugs, risk of myopathy, rhabdomyolysis, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• loxapine
Quviviq (daridorexant)

+

loxapine

1 interaction

Monitor/Modify Tx

daridorexant + loxapine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lumateperone
Quviviq (daridorexant)

+

lumateperone

1 interaction

Monitor/Modify Tx

daridorexant + lumateperone

monitor ECG; consider decr. dose of one or both drugs: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• lurasidone
Quviviq (daridorexant)

+

lurasidone

1 interaction

Monitor/Modify Tx

daridorexant + lurasidone

monitor ECG; consider decr. dose of one or both drugs: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• lurbinectedin
Quviviq (daridorexant)

+

lurbinectedin

1 interaction

Monitor/Modify Tx

daridorexant + lurbinectedin

monitor CBC: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• mavorixafor
Quviviq (daridorexant)

+

mavorixafor

1 interaction

Monitor/Modify Tx

daridorexant + mavorixafor

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• meclizine
Quviviq (daridorexant)

+

meclizine

1 interaction

Monitor/Modify Tx

daridorexant + meclizine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• melatonin
Quviviq (daridorexant)

+

melatonin

1 interaction

Monitor/Modify Tx

daridorexant + melatonin

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• meprobamate
Quviviq (daridorexant)

+

meprobamate

1 interaction

Monitor/Modify Tx

daridorexant + meprobamate

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• methocarbamol
Quviviq (daridorexant)

+

methocarbamol

1 interaction

Monitor/Modify Tx

daridorexant + methocarbamol

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• methohexital
Quviviq (daridorexant)

+

methohexital

1 interaction

Monitor/Modify Tx

daridorexant + methohexital

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• methsuximide
Quviviq (daridorexant)

+

methsuximide

1 interaction

Monitor/Modify Tx

daridorexant + methsuximide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• methyldopa
Quviviq (daridorexant)

+

methyldopa

1 interaction

Monitor/Modify Tx

daridorexant + methyldopa

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• metyrapone
Quviviq (daridorexant)

+

metyrapone

1 interaction

Monitor/Modify Tx

daridorexant + metyrapone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• metyrosine
Quviviq (daridorexant)

+

metyrosine

1 interaction

Monitor/Modify Tx

daridorexant + metyrosine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• milnacipran
Quviviq (daridorexant)

+

milnacipran

1 interaction

Monitor/Modify Tx

daridorexant + milnacipran

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• milsaperidone
Quviviq (daridorexant)

+

milsaperidone

1 interaction

Monitor/Modify Tx

daridorexant + milsaperidone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• mirtazapine
Quviviq (daridorexant)

+

mirtazapine

1 interaction

Monitor/Modify Tx

daridorexant + mirtazapine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• mobocertinib
Quviviq (daridorexant)

+

mobocertinib

1 interaction

Monitor/Modify Tx

daridorexant + mobocertinib

monitor ECG: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. daridorexant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• molindone
Quviviq (daridorexant)

+

molindone

1 interaction

Monitor/Modify Tx

daridorexant + molindone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• morphine
Quviviq (daridorexant)

+

morphine

1 interaction

Monitor/Modify Tx

daridorexant + morphine

monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. morphine levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited, additive effects)

• mosunetuzumab
Quviviq (daridorexant)

+

mosunetuzumab

1 interaction

Monitor/Modify Tx

daridorexant + mosunetuzumab

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• mycophenolate mofetil
Quviviq (daridorexant)

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

daridorexant + mycophenolate mofetil

consider decr. daridorexant dose: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• nalbuphine
Quviviq (daridorexant)

+

nalbuphine

1 interaction

Monitor/Modify Tx

daridorexant + nalbuphine

monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• naltrexone
Quviviq (daridorexant)

+

naltrexone

1 interaction

Monitor/Modify Tx

daridorexant + naltrexone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• naratriptan
Quviviq (daridorexant)

+

naratriptan

1 interaction

Monitor/Modify Tx

daridorexant + naratriptan

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• nelarabine
Quviviq (daridorexant)

+

nelarabine

1 interaction

Monitor/Modify Tx

daridorexant + nelarabine

consider decr. dose of one or both drugs; withhold nelarabine if Grade 2 or greater somnolence occurs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• nifedipine
Quviviq (daridorexant)

+

nifedipine

1 interaction

Monitor/Modify Tx

daridorexant + nifedipine

monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• nilotinib
Quviviq (daridorexant)

+

nilotinib

1 interaction

Monitor/Modify Tx

daridorexant + nilotinib

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• nimodipine
Quviviq (daridorexant)

+

nimodipine

1 interaction

Monitor/Modify Tx

daridorexant + nimodipine

monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• nirogacestat
Quviviq (daridorexant)

+

nirogacestat

1 interaction

Monitor/Modify Tx

daridorexant + nirogacestat

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• nisoldipine
Quviviq (daridorexant)

+

nisoldipine

1 interaction

Monitor/Modify Tx

daridorexant + nisoldipine

monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• nortriptyline
Quviviq (daridorexant)

+

nortriptyline

1 interaction

Monitor/Modify Tx

daridorexant + nortriptyline

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• olanzapine
Quviviq (daridorexant)

+

olanzapine

1 interaction

Monitor/Modify Tx

daridorexant + olanzapine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

• oliceridine
Quviviq (daridorexant)

+

oliceridine

1 interaction

Monitor/Modify Tx

daridorexant + oliceridine

monitor respiratory rate, BP, ECG; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. oliceridine levels, risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• opicapone
Quviviq (daridorexant)

+

opicapone

1 interaction

Monitor/Modify Tx

daridorexant + opicapone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• opium
Quviviq (daridorexant)

+

opium

1 interaction

Monitor/Modify Tx

daridorexant + opium

monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• orphenadrine
Quviviq (daridorexant)

+

orphenadrine

1 interaction

Monitor/Modify Tx

daridorexant + orphenadrine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• oxazepam
Quviviq (daridorexant)

+

oxazepam

1 interaction

Monitor/Modify Tx

daridorexant + oxazepam

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• oxcarbazepine
Quviviq (daridorexant)

+

oxcarbazepine

1 interaction

Monitor/Modify Tx

daridorexant + oxcarbazepine

consider dose adjustment of one or both drugs: combo may decr. daridorexant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• oxybutynin
Quviviq (daridorexant)

+

oxybutynin

1 interaction

Monitor/Modify Tx

daridorexant + oxybutynin

decr. dose of one or both drugs or consider oxybutynin transdermal patch: combo may incr. risk of CNS depression, psychomotor impairment; somnolence less likely with oxybutynin transdermal patch (additive effects)

• oxymorphone
Quviviq (daridorexant)

+

oxymorphone

1 interaction

Monitor/Modify Tx

daridorexant + oxymorphone

monitor respiratory rate; decr. oxymorphone start dose by at least 50%, consider decr. daridorexant dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• paliperidone
Quviviq (daridorexant)

+

paliperidone

1 interaction

Monitor/Modify Tx

daridorexant + paliperidone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• paroxetine
Quviviq (daridorexant)

+

paroxetine

1 interaction

Monitor/Modify Tx

daridorexant + paroxetine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• passion flower
Quviviq (daridorexant)

+

passion flower

1 interaction

Monitor/Modify Tx

daridorexant + passion flower

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pemigatinib
Quviviq (daridorexant)

+

pemigatinib

1 interaction

Monitor/Modify Tx

daridorexant + pemigatinib

monitor phosphate: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

• pentazocine
Quviviq (daridorexant)

+

pentazocine

1 interaction

Monitor/Modify Tx

daridorexant + pentazocine

monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• perampanel
Quviviq (daridorexant)

+

perampanel

1 interaction

Monitor/Modify Tx

daridorexant + perampanel

consider dose adjustment of one or both drugs: combo may decr. daridorexant levels, efficacy if on perampanel 12 mg/day; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• perphenazine
Quviviq (daridorexant)

+

perphenazine

1 interaction

Monitor/Modify Tx

daridorexant + perphenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pheniramine
Quviviq (daridorexant)

+

pheniramine

1 interaction

Monitor/Modify Tx

daridorexant + pheniramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pramipexole
Quviviq (daridorexant)

+

pramipexole

1 interaction

Monitor/Modify Tx

daridorexant + pramipexole

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pregabalin
Quviviq (daridorexant)

+

pregabalin

1 interaction

Monitor/Modify Tx

daridorexant + pregabalin

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• procarbazine
Quviviq (daridorexant)

+

procarbazine

1 interaction

Monitor/Modify Tx

daridorexant + procarbazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• prochlorperazine
Quviviq (daridorexant)

+

prochlorperazine

1 interaction

Monitor/Modify Tx

daridorexant + prochlorperazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• propofol
Quviviq (daridorexant)

+

propofol

1 interaction

Monitor/Modify Tx

daridorexant + propofol

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• protriptyline
Quviviq (daridorexant)

+

protriptyline

1 interaction

Monitor/Modify Tx

daridorexant + protriptyline

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pyrilamine
Quviviq (daridorexant)

+

pyrilamine

1 interaction

Monitor/Modify Tx

daridorexant + pyrilamine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• quetiapine
Quviviq (daridorexant)

+

quetiapine

1 interaction

Monitor/Modify Tx

daridorexant + quetiapine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• quinidine (antiarrhythmic)
Quviviq (daridorexant)

+

quinidine (antiarrhythmic)

1 interaction

Monitor/Modify Tx

daridorexant + quinidine (antiarrhythmic)

monitor quinidine levels, ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• ranolazine
Quviviq (daridorexant)

+

ranolazine

1 interaction

Monitor/Modify Tx

daridorexant + ranolazine

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• rasagiline
Quviviq (daridorexant)

+

rasagiline

1 interaction

Monitor/Modify Tx

daridorexant + rasagiline

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• red yeast rice
Quviviq (daridorexant)

+

red yeast rice

1 interaction

Monitor/Modify Tx

daridorexant + red yeast rice

monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, red yeast rice contains varying amounts of lovastatin)

• remifentanil
Quviviq (daridorexant)

+

remifentanil

1 interaction

Monitor/Modify Tx

daridorexant + remifentanil

monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• remimazolam
Quviviq (daridorexant)

+

remimazolam

1 interaction

Monitor/Modify Tx

daridorexant + remimazolam

monitor respiratory rate; consider decr. dose of one or both drugs; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• rilzabrutinib
Quviviq (daridorexant)

+

rilzabrutinib

1 interaction

Monitor/Modify Tx

daridorexant + rilzabrutinib

adjust max daridorexant dose to 25 mg/day: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• risperidone
Quviviq (daridorexant)

+

risperidone

1 interaction

Monitor/Modify Tx

daridorexant + risperidone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rizatriptan
Quviviq (daridorexant)

+

rizatriptan

1 interaction

Monitor/Modify Tx

daridorexant + rizatriptan

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ropinirole
Quviviq (daridorexant)

+

ropinirole

1 interaction

Monitor/Modify Tx

daridorexant + ropinirole

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rotigotine transdermal
Quviviq (daridorexant)

+

rotigotine transdermal

1 interaction

Monitor/Modify Tx

daridorexant + rotigotine transdermal

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rufinamide
Quviviq (daridorexant)

+

rufinamide

1 interaction

Monitor/Modify Tx

daridorexant + rufinamide

consider dose adjustment of one or both drugs: combo may decr. daridorexant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• safinamide
Quviviq (daridorexant)

+

safinamide

1 interaction

Monitor/Modify Tx

daridorexant + safinamide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• selegiline
Quviviq (daridorexant)

+

selegiline

1 interaction

Monitor/Modify Tx

daridorexant + selegiline

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• selegiline transdermal
Quviviq (daridorexant)

+

selegiline transdermal

1 interaction

Monitor/Modify Tx

daridorexant + selegiline transdermal

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• selinexor
Quviviq (daridorexant)

+

selinexor

1 interaction

Monitor/Modify Tx

daridorexant + selinexor

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• selpercatinib
Quviviq (daridorexant)

+

selpercatinib

1 interaction

Monitor/Modify Tx

daridorexant + selpercatinib

monitor ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• sertraline
Quviviq (daridorexant)

+

sertraline

1 interaction

Monitor/Modify Tx

daridorexant + sertraline

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• sevabertinib
Quviviq (daridorexant)

+

sevabertinib

1 interaction

Monitor/Modify Tx

daridorexant + sevabertinib

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• sevoflurane
Quviviq (daridorexant)

+

sevoflurane

1 interaction

Monitor/Modify Tx

daridorexant + sevoflurane

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• sirolimus
Quviviq (daridorexant)

+

sirolimus

1 interaction

Monitor/Modify Tx

daridorexant + sirolimus

monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• solifenacin
Quviviq (daridorexant)

+

solifenacin

1 interaction

Monitor/Modify Tx

daridorexant + solifenacin

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• stiripentol
Quviviq (daridorexant)

+

stiripentol

1 interaction

Monitor/Modify Tx

daridorexant + stiripentol

consider dose adjustment of one or both drugs: combo may incr. or decr. daridorexant levels, incr. risk of CNS depression, psychomotor impairment, other adverse effects or decr. efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism possibly induced)

• sufentanil
Quviviq (daridorexant)

+

sufentanil

1 interaction

Monitor/Modify Tx

daridorexant + sufentanil

monitor respiratory rate; decr. sufentanil start dose or frequency, consider decr. daridorexant dose, use lowest effective doses: combo may incr. sufentanil levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• sumatriptan
Quviviq (daridorexant)

+

sumatriptan

1 interaction

Monitor/Modify Tx

daridorexant + sumatriptan

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tacrolimus
Quviviq (daridorexant)

+

tacrolimus

1 interaction

Monitor/Modify Tx

daridorexant + tacrolimus

monitor tacrolimus levels, ECG, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• tadalafil
Quviviq (daridorexant)

+

tadalafil

1 interaction

Monitor/Modify Tx

daridorexant + tadalafil

monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

• talazoparib
Quviviq (daridorexant)

+

talazoparib

1 interaction

Monitor/Modify Tx

daridorexant + talazoparib

monitor CBC: combo may incr. talazoparib levels, risk of myelosuppression, other adverse effects (P-gp-mediated transport inhibited)

• taletrectinib
Quviviq (daridorexant)

+

taletrectinib

1 interaction

Monitor/Modify Tx

daridorexant + taletrectinib

monitor ECG: combo may incr. taletrectinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• tapentadol
Quviviq (daridorexant)

+

tapentadol

1 interaction

Monitor/Modify Tx

daridorexant + tapentadol

monitor respiratory rate, BP; decrease dose of one or both drugs, use lowest effective doses and shortest duration of concomitant treatment: combo may increase risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• temsirolimus
Quviviq (daridorexant)

+

temsirolimus

1 interaction

Monitor/Modify Tx

daridorexant + temsirolimus

monitor CBC: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• tenofovir alafenamide
Quviviq (daridorexant)

+

tenofovir alafenamide

1 interaction

Monitor/Modify Tx

daridorexant + tenofovir alafenamide

if tenofovir alafenamide not admin. w/ cobicistat, monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited)

• tenofovir disoproxil
Quviviq (daridorexant)

+

tenofovir disoproxil

1 interaction

Monitor/Modify Tx

daridorexant + tenofovir disoproxil

monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited)

• tetrabenazine
Quviviq (daridorexant)

+

tetrabenazine

1 interaction

Monitor/Modify Tx

daridorexant + tetrabenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• thioridazine
Quviviq (daridorexant)

+

thioridazine

1 interaction

Monitor/Modify Tx

daridorexant + thioridazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• thiotepa
Quviviq (daridorexant)

+

thiotepa

1 interaction

Monitor/Modify Tx

daridorexant + thiotepa

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• thiothixene
Quviviq (daridorexant)

+

thiothixene

1 interaction

Monitor/Modify Tx

daridorexant + thiothixene

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tiagabine
Quviviq (daridorexant)

+

tiagabine

1 interaction

Monitor/Modify Tx

daridorexant + tiagabine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tizanidine
Quviviq (daridorexant)

+

tizanidine

1 interaction

Monitor/Modify Tx

daridorexant + tizanidine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tolcapone
Quviviq (daridorexant)

+

tolcapone

1 interaction

Monitor/Modify Tx

daridorexant + tolcapone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tolterodine
Quviviq (daridorexant)

+

tolterodine

1 interaction

Monitor/Modify Tx

daridorexant + tolterodine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tolvaptan
Quviviq (daridorexant)

+

tolvaptan

1 interaction

Monitor/Modify Tx

daridorexant + tolvaptan

consider decr. tolvaptan dose: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• topiramate
Quviviq (daridorexant)

+

topiramate

1 interaction

Monitor/Modify Tx

daridorexant + topiramate

consider dose adjustment of one or both drugs: combo may decr. daridorexant levels, efficacy, especially with topiramate doses >200 mg/day; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• tramadol
Quviviq (daridorexant)

+

tramadol

1 interaction

Monitor/Modify Tx

daridorexant + tramadol

monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

• trazodone
Quviviq (daridorexant)

+

trazodone

1 interaction

Monitor/Modify Tx

daridorexant + trazodone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trifluoperazine
Quviviq (daridorexant)

+

trifluoperazine

1 interaction

Monitor/Modify Tx

daridorexant + trifluoperazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trihexyphenidyl
Quviviq (daridorexant)

+

trihexyphenidyl

1 interaction

Monitor/Modify Tx

daridorexant + trihexyphenidyl

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trimipramine
Quviviq (daridorexant)

+

trimipramine

1 interaction

Monitor/Modify Tx

daridorexant + trimipramine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• triprolidine
Quviviq (daridorexant)

+

triprolidine

1 interaction

Monitor/Modify Tx

daridorexant + triprolidine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trospium
Quviviq (daridorexant)

+

trospium

1 interaction

Monitor/Modify Tx

daridorexant + trospium

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ubrogepant
Quviviq (daridorexant)

+

ubrogepant

1 interaction

Monitor/Modify Tx

daridorexant + ubrogepant

limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• valbenazine
Quviviq (daridorexant)

+

valbenazine

1 interaction

Monitor/Modify Tx

daridorexant + valbenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• valerian
Quviviq (daridorexant)

+

valerian

1 interaction

Monitor/Modify Tx

daridorexant + valerian

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• valproic acid
Quviviq (daridorexant)

+

valproic acid

1 interaction

Monitor/Modify Tx

daridorexant + valproic acid

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• vardenafil
Quviviq (daridorexant)

+

vardenafil

1 interaction

Monitor/Modify Tx

daridorexant + vardenafil

monitor ECG: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

• venlafaxine
Quviviq (daridorexant)

+

venlafaxine

1 interaction

Monitor/Modify Tx

daridorexant + venlafaxine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• verapamil
Quviviq (daridorexant)

+

verapamil

1 interaction

Monitor/Modify Tx

daridorexant + verapamil

adjust max daridorexant dose to 25 mg/day: combo may incr. levels of both drugs, risk of hypotension, bradycardia, AV block, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• vigabatrin
Quviviq (daridorexant)

+

vigabatrin

1 interaction

Monitor/Modify Tx

daridorexant + vigabatrin

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• vilazodone
Quviviq (daridorexant)

+

vilazodone

1 interaction

Monitor/Modify Tx

daridorexant + vilazodone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• viloxazine
Quviviq (daridorexant)

+

viloxazine

1 interaction

Monitor/Modify Tx

daridorexant + viloxazine

consider decr. dose of one or both drugs: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• vinblastine
Quviviq (daridorexant)

+

vinblastine

1 interaction

Monitor/Modify Tx

daridorexant + vinblastine

monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects; may decr. daridorexant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• vincristine
Quviviq (daridorexant)

+

vincristine

1 interaction

Monitor/Modify Tx

daridorexant + vincristine

monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

• vinorelbine
Quviviq (daridorexant)

+

vinorelbine

1 interaction

Monitor/Modify Tx

daridorexant + vinorelbine

monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

• warfarin
Quviviq (daridorexant)

+

warfarin

1 interaction

Monitor/Modify Tx

daridorexant + warfarin

monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

• zanubrutinib
Quviviq (daridorexant)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

daridorexant + zanubrutinib

monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects; may decr. daridorexant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• ziconotide
Quviviq (daridorexant)

+

ziconotide

1 interaction

Monitor/Modify Tx

daridorexant + ziconotide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ziprasidone
Quviviq (daridorexant)

+

ziprasidone

1 interaction

Monitor/Modify Tx

daridorexant + ziprasidone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zolmitriptan
Quviviq (daridorexant)

+

zolmitriptan

1 interaction

Monitor/Modify Tx

daridorexant + zolmitriptan

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zonisamide
Quviviq (daridorexant)

+

zonisamide

1 interaction

Monitor/Modify Tx

daridorexant + zonisamide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)